|
News About The
Antibody Market |
Avastin®, already approved to treat patients
with advanced colorectal
and advanced non- small cell lung cancer, is Genentech's biggest seller
at a hefty $2.3 billion in U.S. sales in 2007. |
|
Erbitux®
sales, excluding the United States, rose to $186 million in
the fourth quarter from $125.8 million a year earlier, according to
ImClone Systems Inc. |
|
The second wave
of therapeutic antibody technologies, encompassing optimized
full size, fully human antibodies as well as the bits and pieces
of individual antibody fragments and alternative binding
domains/scaffolds is driving the formation of innovative
technology platforms. While biotechs have led the race towards
the discovery of novel technologies, big pharma has taken over
the reigns for the development of many of these future
therapeutic drugs. © 2008
BioMarket Group
|
|
United States
Patent And Trademark Office |
Cytolin®
Related
Patents
Our Registered
Trademarks
76354867 Our Logo
74557265 CYTODYN
74557264 CYTOLIN
|
The Company also has foreign counterparts
issued and pending, and patents licensed from a unit of Harvard
University for the next generation of products. |
 |
|
|
First Drug in Clinical Trials Designed to
Let The Immune System Control HIV Infection
HIV infects other species, such as chimpanzees.
But only humans get sick from HIV infection. In the early 1990s,
several teams of university-based scientists
reported
in the peer-review literature that this unique response of
humans to HIV infection is because of a
flaw in the human immune system. Cytolin®, a monoclonal antibody, is
designed to correct that flaw. This is different from
"reconstituting" the immune system, which can make patients sick
("immune reconstitution syndrome"). With the human immune
system working better, we would expect it to do a better job of
controlling HIV infection as shown by the data below from an
early clinical trial.
Because a properly functioning immune system should control any strain of HIV, Cytolin®
is intended to help patients infected with drug-resistant
strains of HIV, and might even prevent drug resistance from developing when used in
combination with antiretroviral drugs. |
Resolution of cutaneous anergy shown at the
top reflects restoration of cell-mediated immune function in five
patients who received an infusion of approximately 0.1 mg/kg Cytolin©,
which was well tolerated. This was correlated with a mean drop in
viremia of 1 log in these treatment naive patients.
Although the
Company has made a commercially reasonable effort to ensure the accuracy of
the contents of this web site, its content has not been reviewed
by an independent auditor or regulatory body and accuracy cannot
be guaranteed. This site was last updated on
07/14/2008.
More information is available from other public
sources, including but not limited to, our historic filings with the
Securities and Exchange Commission and news releases.
Forward-looking statements
are statements that are not historical facts. The Company's
management makes forward-looking statements concerning the
Company's expected future operations, performance and other
developments. These forward-looking statements are necessarily
estimates based upon current information and projections and involve a number of risks and uncertainties,
including but not limited to, the failure of preliminary results
from scientific studies to reflect the results from more
comprehensive studies. There can be no assurance that such
risks and uncertainties, or other factors, will not affect the
accuracy of such forward-looking statements. It is impossible to
identify all factors that could cause actual results to differ
materially from those estimated by the Company. They include,
but are not limited to, government regulation, managing and
maintaining growth, victimization by white-collar offenders, and
the effects of adverse publicity, litigation, competition,
and other factors that may be
identified from time to time in the Company's announcements.
|
